 Leucovorin
"Leucovorin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
| Descriptor ID |
D002955
|
| MeSH Number(s) |
D03.633.100.733.631.400.800.350.450 D08.211.840.300.500
|
| Concept/Terms |
Leucovorin- Leucovorin
- Folinic Acid-SF
- Folinic Acid SF
- Leukovorin
- Leukovorum
- Folinic Acid
- Acid, Folinic
Citrovorum Factor- Citrovorum Factor
- Factor, Citrovorum
- Calcium Leucovorin
- Leucovorin, Calcium
- Calcium Folinate
- Folinate, Calcium
N(5)-Formyltetrahydrofolate- N(5)-Formyltetrahydrofolate
- 5-Formyltetrahydropteroylglutamate
- 5 Formyltetrahydropteroylglutamate
- 5-Formyltetrahydrofolate
- 5 Formyltetrahydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Leucovorin".
Below are MeSH descriptors whose meaning is more specific than "Leucovorin".
This graph shows the total number of publications written about "Leucovorin" by people in this website by year, and whether "Leucovorin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 3 | 3 | | 2014 | 1 | 3 | 4 | | 2016 | 0 | 3 | 3 | | 2017 | 0 | 3 | 3 | | 2019 | 0 | 4 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 2 | 2 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Leucovorin" by people in Profiles.
-
Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park). 2022 10 07; 36(10):604-608.
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Ann Surg Oncol. 2022 08; 29(8):5051-5052.
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol. 2022 Aug; 29(8):5038-5050.
-
Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022 03 10; 40(8):892-910.
-
Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, Segersv?rd R, Arnelo U, Del Chiaro M. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Ann Surg. 2021 03 01; 273(3):579-586.
-
van Roessel S, van Veldhuisen E, Klompmaker S, Janssen QP, Abu Hilal M, Alseidi A, Balduzzi A, Balzano G, Bassi C, Berrevoet F, Bonds M, Busch OR, Butturini G, Del Chiaro M, Conlon KC, Falconi M, Frigerio I, Fusai GK, Gagni?re J, Griffin O, Hackert T, Halimi A, Klaiber U, Labori KJ, Malleo G, Marino MV, Mortensen MB, Nikov A, Lesurtel M, Keck T, Kleeff J, Pand? R, Pfeiffer P, Pietrasz D, Roberts KJ, Sa Cunha A, Salvia R, Strobel O, Tarvainen T, Bossuyt PM, van Laarhoven HWM, Wilmink JW, Groot Koerkamp B, Besselink MG. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncol. 2020 Nov 01; 6(11):1733-1740.
-
Li W, Wang W, Liao P, Song K, Zhu Z, Wang K, Liu Z, Zhang W, Xie S, He Y, Mcleod HL, Chen L. High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients. Pharmacogenomics. 2020 07; 21(11):751-759.
-
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):782-794.
-
Ng SY, Colborn KL, Cambridge L, Cercek A, Reidy-Lagunes DL, Segal N, Stadler Z, Saltz LB, Paty PB, Guillem J, Weiser MR, Nash G, Garcia-Aguilar J, Goodman KA. Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. Clin Colorectal Cancer. 2019 09; 18(3):167-174.
-
Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Ol?h A, Rawcliffe CL, Campbell F, Strobel O, B?chler MW, Neoptolemos JP. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019 03; 269(3):520-529.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|